| |
| |
|
| Insider
Information: |
Heller Frances K |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
104,260 |
|
|
Indirect Shares
|
173 |
|
|
| Direct
Value |
$648,222 |
|
|
|
Indirect Value
|
$5,031 |
|
|
| Total
Shares |
104,433 |
|
|
| Total
Value |
$653,252 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Exelixis Inc |
EXEL |
EVP, Business Developm... |
2011-05-15 |
17,125 |
2011-05-15 |
129 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
SVP, Business Developm... |
2014-03-10 |
4,174 |
2014-03-10 |
44 |
Premium* |
|
|
Larimar Therapeutics Inc |
LRMR |
Director |
2017-10-13 |
47,961 |
2016-07-22 |
0 |
Premium* |
|
|
Monterey Bio Acquisition Corp |
MTRY |
Director |
2021-09-30 |
35,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
15 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MTRY |
Monterey Bio Acquisition ... |
Director |
– • – |
2021-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,000 |
|
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • – |
2017-10-13 |
4 |
B |
$3.90 |
$38,988 |
D/D |
10,000 |
47,961 |
2.39 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • – |
2016-12-19 |
4 |
B |
$3.23 |
$32,290 |
D/D |
10,000 |
30,000 |
2.39 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • – |
2016-11-15 |
4 |
B |
$3.54 |
$35,434 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
| LRMR |
Larimar Therapeutics Inc |
Director |
– • – |
2016-07-22 |
4 |
B |
$2.99 |
$29,900 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP, Business Development |
• – – |
2014-03-10 |
4 |
D |
$56.14 |
$53,782 |
D/D |
(958) |
4,174 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP, Business Development |
• – – |
2014-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
730 |
5,132 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP, Business Development |
• – – |
2014-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,609 |
4,402 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP, Business Development |
• – – |
2013-10-01 |
4 |
D |
$47.24 |
$78,324 |
D/D |
(1,658) |
2,793 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
SVP, Business Development |
• – – |
2013-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,451 |
4,451 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, Business Development |
• – – |
2011-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,125 |
17,125 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, Business Development |
• – – |
2011-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
14,000 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, Business Development |
• – – |
2009-11-02 |
4 |
AS |
$6.19 |
$15,658 |
D/D |
(2,529) |
1,500 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, Business Development |
• – – |
2009-06-03 |
4 |
AS |
$5.00 |
$53,126 |
D/D |
(10,609) |
1,500 |
0 |
- |
|
| EXEL |
Exelixis Inc |
EVP, Business DevelopmentOffic |
• – – |
2008-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
15 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
